NOVAVAX (NVAX)
$7.58
0.26 (3.43%)
NVAX Stock Quote Delayed 30 Minutes
Novavax Looks Like a Bargain with Its Low Forward Earnings Multiple
Novavax looks cheap at just 6 times forward earnings. NVAX stock is likely worth at least 85% more at $314 once it receives vaccine approval.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$7.17
Market Cap
1.17B
PE Ratio
-3.82
EPS
-1.9818
Volume (Avg. Vol.)
3.86M
Day's Range
$7.17 - $7.42
52-Week Range
$3.81 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and NOVAVAX News
Novavax Looks Primed and Ready for a Vaccine Comeback
NVAX stock looks enticing now after falling steeply due to delays in FDA emergency approval as well as other manufacturing issues.
Novavax Is a Much Better Growth Buy Than Moderna Here
NVAX benefits from several near-term catalysts that will push the stock higher, making it a better buy than more mature enterprises.
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
NVAX stock's prospects in November depend upon regulatory developments regarding its Covid-19 vaccine candidate
Novavax Stock Rises as UK Covid Vax Okay Sought, Other Growth Anticipated
Novavax stock offers a unique opportunity to invest in a late stage biotech built on cutting-edge vaccine technology, NVAX stock has surged on its Covid-19 vaccine potential, but don't forget its work on a universal vaccine for seasonal influenza.
Novavax Just Caught a Big Break
Politico’s article about Novavax’s inability to manufacture its Covid-19 vaccine wasn't good for NVAX stock. Down 16% since, should you buy?
Don’t Count Novavax Out; The World Still Needs Vaccines
NVAX stock has suffered some setbacks, but with only half the world population vaccinated, patient investors are likely to be rewarded.
NVAX Stock Soars 6% as Novavax Reaches Key Vaccine Milestone
Novavax may be on the verge of good news from U.K. regulators. NVAX stock is reacting well to the impending news.
Novavax is Now a Riskier Play, but Still One to Keep Your Eye On
NVAX stock is even more of a gamble thanks to manufacturing issues, but the next move for the beaten-down shares could still be up.
Novavax Is Set to Win on the Increasing Necessity of Booster Shots
NVAX stock has dropped a significant amount recently, but this could be a terrific buying opportunity for savvy long-term investors.
While Much Riding on FDA Nod, Novavax Fortunes Are More Than Just Covid
The FDA approval is a near term catalyst that will take NVAX stock to new highs over the coming months. Buy NVAX stock in the dip.
4 Top Stock Trades for Thursday: AMD, NFLX, WISH, NVAX
Advanced Micro Devices, Netflix, ContextLogic and Novavax were our top stock trades for Thursday. Now, here's what the charts are saying.
It’s Time to Secure Those Profits You Earned from Novavax
While NVAX stock had an excellent run, the vaccination market is practically saturated, meaning investors should consider profit-taking.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
I hope you're ready for another busy day of trading because we're starting it with the biggest pre-market stock movers for Wednesday.
Novavax Stock Fortunes Are Still Awaiting the Magical Headline
NVAX stock is up 3,480% in two years but the real price fight is awaiting headlines from management. Meanwhile, owning it requires conviction.
Novavax Will Be Volatile Until the Company Delivers Answers
NVAX stock has been making some volatile moves in 2021. And that volatility will continue until its Covid-19 vaccine gets regulatory approval.
Novavax Stock Will Find Its Bottom, But Probably not Soon
Down nearly 40% over the past month, NVAX stock has been on a steep decline that appears to be accelerating. At its current price of $163.06 per share, Novavax's stock is now 50% below its all-time high of $331.68 reached in February of this year. With the current slide showing no signs of stopping, shareholders may want to cut their losses.
Novavax Stock Got Merck-ed, but Don’t Dump Your Shares Now
NVAX stock still has plenty of value as Novavax has a rich and diverse clinical pipeline, including a promising influenza vaccine candidate.
